Sign in
Taking people in United StatesPhase 1

Tests PLZ4-coated paclitaxel micelles for early bladder cancer

Tests a targeted chemotherapy delivered into the bladder in adults with bladder cancer.

Key facts

Who runs it
VA Office of Research and Development
Where
Boston, United StatesSee the site
Trial code
Registry title
A Phase I Intravesical PPM Therapy for NMIBC
Status
Recruiting
Phase
Phase 1
People taking part
29 people, planned
Started
10 Oct 2022
Expected to end
31 Dec 2027
Type of study
Interventional
Treatments tested
  • PLZ4-coated paclitaxel-loaded micelles (PPM)
Record updated
17 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with bladder cancer that has not grown into the bladder muscle and did not respond to, or could not tolerate, BCG treatment. The new drug PPM is placed into the bladder.

Age
18 years or older
Sex
All sexes can join
Disease stage
Non-muscle-invasive bladder cancer (carcinoma in situ or urothelial carcinoma, with or without T1), with no sign of growth into the bladder muscle. The cancer must not have responded to BCG, or the person could not tolerate BCG.
Earlier treatment
Must have had BCG treatment that did not work, or could not tolerate BCG. Must have refused or cannot have a radical cystectomy (bladder removal). No radiotherapy, chemotherapy or other immunotherapy at the same time or planned before response evaluation.

Main reasons for not taking part

  • Cancer in the upper urinary tract
  • Cancer that has spread to nearby or distant parts of the body
  • Serious heart problems, such as class III or IV heart failure or a heart attack within 6 months
  • Bleeding disorder, or taking medicines that affect blood clotting (aspirin 81 mg once a day is allowed)
  • Pregnant or nursing women

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Patients must meet all of the following criteria to be eligible for study entry
  • Histologically confirmed bladder carcinoma in situ (CIS) urothelial or urothelial carcinoma, with or without T1 cancer. Patients are eligible if the biopsy was done within 3 months of enrollment and a cystoscopy demonstrates no gross disease invasion into muscularis propria within 4 weeks of enrollment
  • Patient must have BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) or intolerance of treatment with BCG. Treatment of pembrolizumab is not an inclusion or exclusion criteria as intravesical taxane probably has comparable efficacy as intravenous pembrolizumab. BCG-unresponsive disease is defined as being at least one of the following:; Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy; Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG therapy; T1 high-grade disease at the first evaluation following an induction BCG course; In this context, adequate BCG therapy is defined as at least one of the following:
  • At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy
  • At least five of six doses of an initial induction course plus at least two of six doses of a second induction course; Refuse or intolerant of a radical cystectomy recommended by the treating urologist as the standard next therapy per urologic guidelines; Performance status: ECOG performance status of 0, 1, or 2 or Karnofsky performance status of 50 or higher; Patient with life expectancy greater than 24 months; No concurrent radiotherapy, chemotherapy, or other immunotherapy; No scheduled radiotherapy, chemotherapy, other immunotherapy, or surgery before the scheduled response evaluation; Recovery from prior treatment side effects that might interfere with the study treatment, in the judgment of the participating urologist; Laboratory tests performed within 14 days of study enrollment:
  • Absolute neutrophil count (AGC/ANC)1,500/uL
  • Platelets100,000/uL [Patients may be transfused to meet this requirement]
  • Hemoglobin 8 g/dL [Patients may be transfused to meet this requirement]
  • Calculated glomerular filtration rate (GFR) 50 mL/min/1.73m2
  • Total bilirubin 2.0 X ULN (< 3 x ULN for patients with Gilbert's syndrome)
  • AST, ALT, ALP 3.0 X ULN; Adequate pulmonary function with no clinical signs of severe pulmonary dysfunction; Negative serum pregnancy test if the study participant is a female and of childbearing potential (non-childbearing is defined as greater than one year postmenopausal or surgically sterilized); Female participants of childbearing potential must adhere to using a medically accepted method of birth control, i.e. a tubal ligation, an approved hormonal contraceptive or an intrauterine device, prior to screening and agree to continue its use during the study and up to 3 months after finishing this study or be surgically sterilized (e.g., hysterectomy or tubal ligation). Males must agree to use barrier methods of birth control while on study; Provide signed informed consent and HIPAA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations

Who cannot take part

  • Concurrent use of other investigational agents
  • Symptomatic congestive heart failure (CHF), severe/unstable angina pectoris, or myocardial infarction within 6 months prior to study entry
  • Patient taking medications that affect coagulation, such as aspirin (aspirin 81 mg oral once daily is allowed), Coumadin/Warfarin, heparin, low molecular weight heparin, direct thrombin inhibitors, and direct factor Xa inhibitors. Other nonsteroidal anti-inflammatory drugs (NSAIDs) are allowed as long as they are discontinued the day before therapy
  • Existence of cancer at the upper urinary tract
  • NYHA (New York Heart Association) Class III or IV heart failure, uncontrollable supraventricular arrhythmias, any history of a ventricular arrhythmia, or other clinical signs of severe cardiac dysfunction
  • Patient has an intractable bleeding disorder (e.g., coagulation factors deficiencies, Von Willebrand Disease)
  • History or evidence of uncontrollable central nervous system (CNS) disease
  • Active systemic infection requiring parenteral antibiotic therapy
  • Psychiatric illness/social situations that would limit compliance with study requirements
  • Other illness that in the opinion of the investigator would exclude the patient from participating in this study
  • Any other malignancy diagnosed within 3 years of trial entry with the exception of:; Basal or squamous cell skin cancers, or; Noninvasive cancer of the cervix, or; Any other cancer deemed to be of low-risk for progression or patient morbidity during trial period, such as localized prostate cancer after definitive treatment and prostate-specific antigen (PSA) less than 0.2 ng/ml
  • Patients who meet any of the following criteria will be excluded from study entry
  • Evidence of regional and/or distant metastasis
  • Women who are pregnant or nursing
  • Patients unwilling to or unable to comply with the protocol
  • Patients with impaired decision-making capacity

Where in United States

  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MABoston, United StatesContact: Chong-Xian Pan, MD PhDTaking people

About the trial

What the trial wants to find out

This clinical trial is to determine the safety and effectiveness of an investigational bladder cancer drug named "PLZ4-coated paclitaxel-loaded nanoscale micelle (PPM)." PPM is tiny particles that contain the chemotherapy drug paclitaxel. PLZ4 is a molecule that can possibly guide PPM to specifically target and deliver paclitaxel into and kill bladder cancer cells. In this trial, PPM will be instilled into the bladder cavity to treat bladder cancer that does not invade into the muscle layer of the bladder and that has failed the treatment of another drug Bacillus Calmette-Guérin (BCG). Up to 29 patients will be enrolled into the trial. The main goal of this trial is to determine the dose of PPM for future clinical trials, assess the toxicity and obtain preliminary data regarding its effectiveness.

The group in the trial

  • Phase I dose-escalation and expansion cohortTreatment being tested

    There are three doses at the dose escalation stage: Dose level I: paclitaxel (PTX) 25 Milligrams (mg) or 0.5 Milligrams (mg)/milliliter (ml); Dose Level II: PTX 50 mg or 1.0 mg/ml; Dose Level III: PTX 75 mg or 1.5 mg/ml. At the expansion cohort, up to 12 patients will be recruited and treated with PPM at the PTX dose of 50 mg or 1.0 mg/ml to determine the efficacy.

    Treatment: PLZ4-coated paclitaxel-loaded micelles (PPM)

Results explained

A paper that names this trial, explained in plain words.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I Trial of Cancer-targeting Micelles for Non-myoinvasive Bladder Cancer
Plain-language title
Tests PLZ4-coated paclitaxel micelles for early bladder cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
17 August 2026